Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TriSalus Life Sciences (TLSI) Gains from Investment Securities (2022 - 2025)

TriSalus Life Sciences (TLSI) has 4 years of Gains from Investment Securities data on record, last reported at $2.6 million in Q4 2025.

  • For Q4 2025, Gains from Investment Securities rose 14572.22% year-over-year to $2.6 million; the TTM value through Sep 2025 reached -$2.6 million, up 90.04%, while the annual FY2023 figure was -$10.3 million, 7957.25% down from the prior year.
  • Gains from Investment Securities reached $2.6 million in Q4 2025 per TLSI's latest filing, up from -$2.5 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $2.6 million in Q4 2025 and bottomed at -$13.7 million in Q2 2024.
  • Average Gains from Investment Securities over 4 years is -$2.9 million, with a median of -$1.6 million recorded in 2024.
  • Peak YoY movement for Gains from Investment Securities: plummeted 5786.74% in 2023, then skyrocketed 14572.22% in 2025.
  • A 4-year view of Gains from Investment Securities shows it stood at $181000.0 in 2022, then tumbled by 5786.74% to -$10.3 million in 2023, then soared by 100.17% to $18000.0 in 2024, then surged by 14572.22% to $2.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Gains from Investment Securities were $2.6 million in Q4 2025, -$2.5 million in Q3 2025, and -$937000.0 in Q2 2025.